Royce & Associates LP Increases Holdings in CareDx, Inc (NASDAQ:CDNA)

Royce & Associates LP increased its stake in shares of CareDx, Inc (NASDAQ:CDNA) by 23.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 484,286 shares of the company’s stock after purchasing an additional 91,000 shares during the period. Royce & Associates LP owned 0.90% of CareDx worth $10,369,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Quarry LP purchased a new stake in shares of CareDx in the third quarter worth about $27,000. Harvest Fund Management Co. Ltd bought a new stake in CareDx during the 3rd quarter worth approximately $52,000. KBC Group NV purchased a new stake in CareDx in the 3rd quarter worth approximately $99,000. Plato Investment Management Ltd boosted its holdings in CareDx by 34.1% in the 4th quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock valued at $116,000 after purchasing an additional 1,370 shares during the period. Finally, Quest Partners LLC grew its position in shares of CareDx by 37.8% during the 3rd quarter. Quest Partners LLC now owns 5,611 shares of the company’s stock valued at $175,000 after purchasing an additional 1,540 shares in the last quarter.

CareDx Stock Performance

CDNA stock opened at $19.27 on Tuesday. The company has a market capitalization of $1.07 billion, a PE ratio of -7.14 and a beta of 1.95. CareDx, Inc has a one year low of $7.42 and a one year high of $34.84. The company’s 50 day moving average price is $22.16 and its two-hundred day moving average price is $24.22.

CareDx (NASDAQ:CDNA) last issued its earnings results on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company had revenue of $86.58 million for the quarter, compared to analysts’ expectations of $84.56 million. On average, research analysts predict that CareDx, Inc will post -0.9 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CDNA. Stephens reiterated an “overweight” rating and issued a $40.00 price objective on shares of CareDx in a research report on Thursday, February 27th. HC Wainwright cut their price objective on CareDx from $26.00 to $25.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Wells Fargo & Company raised shares of CareDx from an “underweight” rating to an “equal weight” rating and lowered their target price for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. Finally, StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research note on Wednesday, February 26th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $31.83.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.